Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Goodwin Lawyers Provide Updates on Biosimilar Litigation (<i>The Center for Biosimilars</i>)

main

12_27 FEATURE Goodwin Lawyers Provide Updates

FEATURE: Goodwin Lawyers Provide Updates on Biosimilar Litigation <i>(The Center for Biosimilars)</i>

Goodwin Lawyers Provide Updates on Biosimilar Litigation (The Center for Biosimilars)

Related Content

BIOSECURE Act Included in Final Draft NDAA Compromise Text

CMS Finalizes Changes to Bona Fide Service Fee Requirements, Alongside Other Adjustments to Medicare Part B Drug Reimbursement Methodology

BIOSECURE Included in Draft National Defense Authorization Act of 2026

Life Sciences and Medtech Policy Update:
Key Things to Know Q4 2025

Move Fast: FDA Is Accepting Submissions for the Pilot Program Class for FDA Commissioner’s National Priority Voucher Program

340B Rebate Pilot Program Proposed by HRSA

DOJ-HHS Announces False Claims Act Working Group, Emphasizes Healthcare Fraud Enforcement Priorities

DLT Pilot Regime: ESMA Report Highlights Legal Hurdles and Regulatory Next Steps

Best Law Firms 2026 Names Goodwin ERISA Litigation Law Firm of the Year and Recognizes 50 Practice Areas

FDA’s New Fast Drug Review Plan Comes with Trade-Offs for Pharma (Bloomberg Law)

Goodwin Named an LMG Life Sciences Life Cycle Firm for the Fourteenth Consecutive Year

Chambers USA 2025 Recognizes a Record Number of Goodwin Practices and Lawyers for Exceptional Client Service

Blueprint Medicines To Be Acquired By Sanofi For $9.5 Billion Including Contingent Value Rights

Trump’s Drug Price Plan Seeks Leverage with FDA Withdrawal Power (Bloomberg Law)

Rare Disease Industry Awaits FDA Chief’s New Drug Pathway Plan (Bloomberg Law)

Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.

Life Sciences

Life Sciences Regulatory & Compliance

Patent Trial & Appeal Board

Hatch-Waxman, Biologics and Biosimilars Litigation